Veraxa Biotech AG (VRXA) Key Metrics
VRXA key metrics, 2023–2025
Fiscal year ended December 31, 2025 · Swiss francsVRXA returns How much profit the business earns on the capital it uses.
Return on assets−48.6 pts
−80.5%
2025 · hover or tap a bar for each year
20232025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20232025
VRXA financial health Debt, liquidity and how easily interest is covered.
Net debtCHF 3.7M
−CHF 1.6M
2025 · hover or tap a bar for each year
20232025
Current ratio−80.2%
0.44
2025 · hover or tap a bar for each year
20232025
VRXA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VRXA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VRXA key metrics in Swiss francs
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Returns & profitability | |||
| Return on equity (ROE) | — | −65.3% | −30.0% |
| Return on invested capital (ROIC) | — | −65.8% | −30.1% |
| Return on assets (ROA) | −80.5% | −31.8% | −18.0% |
| Return on tangible assets | — | −333.6% | −118.1% |
| Financial health | |||
| Cash & short-term investments | CHF 1.6M | CHF 5.4M | CHF 11.4M |
| Net debt | −CHF 1.6M | −CHF 5.4M | −CHF 11.4M |
| Current ratio | 0.44 | 2.20 | 7.39 |
| Quick ratio | 0.44 | 2.20 | 7.39 |
| Working capital | −CHF 3.7M | CHF 3.1M | CHF 10.3M |
| Invested capital | −CHF 17.4M | CHF 25.7M | CHF 43.8M |
| Tangible asset value | −CHF 90.5M | −CHF 45.3M | −CHF 22.8M |
| Net current asset value | −CHF 93.7M | −CHF 48.1M | −CHF 24.9M |
| Capital allocation | |||
| Capex / revenue | 1,866.2% | — | — |
| Capex / depreciation | 0.22 | 0.06 | 0.13 |
| Stock-based compensation / revenue | 224,807.1% | — | — |
| R&D / revenue | 43,815.1% | — | — |
| SG&A / revenue | 229,961.1% | — | — |
| Efficiency | |||
| Days payables outstanding | 43,063.9 | — | — |
| Payables turnover | 0.01 | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 |
| Average payables | CHF 939,738 | CHF 550,059 | CHF 611,575 |
| Intangibles / total assets | 92.5% | 90.1% | 84.8% |
Computed from VRXA's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Swiss francs; data from EODHD. Averages use the opening and closing balance of each year.
VRXA valuation and financial ratios
See the VRXA income statement, the VRXA chart for price history, or the VRXA stock overview for the latest quote and news.
VRXA key metrics FAQ
What is Veraxa Biotech's current ratio?
Veraxa Biotech's current ratio was 0.44 at the end of fiscal 2025: current assets were 0.44 times current liabilities.